External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Sales from injectables in the US experienced a decline of $102 Mn, representing a 1.8% QoQ drop.</li><li>This decline was attributed to substantial price erosion, despite an approximate $30 Mn increase in revenue from Revlimid.</li><li>Gross margins decreased by 23 basis points QoQ, and EBITDA margins fell by 67 basis points QoQ, reflecting the pressure on profitability from pricing pressures.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sales from injectables in the US experienced a decline of $102 Mn, representing a 1.8% QoQ drop.This decline was attributed to substantial price erosion, despite an approximate $30 Mn increase in revenue from Revlimid.Gross margins decreased by 23 basis points QoQ, and EBITDA margins fell by 67 basis points QoQ, reflecting the pressure on profitability from pricing pressures.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Fall Short of Expectations Amidst Mixed Market Performance